Accessing Ketamine Therapy Internationally: A Global Guide

Ketamine Therapy Beyond the United States

Ketamine therapy for depression and other mental health conditions has gained significant traction in the United States, but the global picture is far more varied. Depending on where you live or travel, access to ketamine-based treatments can range from readily available to effectively nonexistent. Legal status, medical culture, regulatory frameworks, and insurance systems all play a role in shaping what is possible in each country.

This guide provides an overview of ketamine therapy access around the world. Whether you live outside the United States, are an expat seeking treatment abroad, or are simply curious about how other countries approach this therapy, the information here will help you understand the landscape and begin exploring your options.

North America

United States

The United States currently has the most developed infrastructure for ketamine therapy. Hundreds of private clinics offer IV ketamine infusions for depression, anxiety, PTSD, and chronic pain. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and is available through certified healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS) program.

Telehealth providers have expanded access to at-home sublingual ketamine across most states. Generic ketamine is used off-label — meaning it is legal for physicians to prescribe but has not gone through the FDA approval process specifically for depression. Insurance coverage for generic ketamine remains limited, while Spravato has broader coverage through most major plans.

The US market is the most competitive, with a wide range of pricing and service models. This is both an advantage (more options) and a challenge (more variation in quality).

Canada

Canada has a growing but less developed ketamine therapy landscape compared to the United States. Ketamine is a legally available medication and can be prescribed off-label by physicians for depression and other mental health conditions. Several clinics in major cities — Toronto, Vancouver, Montreal, Calgary — offer IV ketamine infusions.

Spravato (esketamine) received Health Canada approval and is available through specialized clinics, though access varies by province. Provincial health insurance plans generally do not cover ketamine for depression, meaning most patients pay out of pocket. Costs are broadly comparable to US pricing, though some clinics offer lower rates due to lower overhead.

Telehealth ketamine services are emerging in Canada, though the regulatory environment is still evolving. Canadian physicians must navigate provincial prescribing regulations that can vary significantly.

Europe

United Kingdom

The UK has a small but growing number of private ketamine clinics, primarily in London and other major cities. Ketamine is a Class B controlled substance in the UK, but it is available for medical use when prescribed by a licensed physician. Private clinics offer IV infusions and nasal spray treatments, typically for treatment-resistant depression.

The National Health Service (NHS) does not routinely offer ketamine therapy for depression, though esketamine (Spravato) has been evaluated by the National Institute for Health and Care Excellence (NICE). Access through the NHS is very limited and typically restricted to specialized treatment-resistant depression programs.

Private treatment costs in the UK range from approximately 300 to 600 GBP per infusion session, with initial series packages available at some clinics. The private ketamine clinic sector is smaller than in the US but is expanding steadily.

European Union

Access varies considerably across EU member states. Some key points:

• Germany has a relatively progressive approach, with several clinics in major cities offering ketamine infusions. Esketamine has been approved by the European Medicines Agency (EMA) and is available in Germany, though access through the public health system can involve waiting periods and strict criteria.
• The Netherlands has a small number of clinics offering ketamine therapy, consistent with the country's generally open approach to mental health treatment innovation.
• France and Spain have more limited access. Esketamine is approved but is primarily available through hospital-based psychiatric programs rather than private clinics. Off-label IV ketamine clinics are uncommon.
• Scandinavian countries (Sweden, Denmark, Norway, Finland) have generally cautious regulatory approaches. Esketamine is available in some hospital settings, but private ketamine clinics are rare. These countries tend to have strong public mental health systems but can be slower to adopt newer treatments outside of clinical trials.
• Eastern Europe has very limited access to ketamine therapy for mental health. The treatment is generally only available in research settings or through a small number of private practitioners.

Overall, the EU landscape is fragmented. The EMA's approval of esketamine has created a pathway for access, but implementation varies enormously by country, and private clinics offering off-label IV ketamine are far less common than in the US.

Australia and New Zealand

Australia

Australia has emerged as one of the more progressive countries for ketamine therapy outside of North America. The Therapeutic Goods Administration (TGA) has approved esketamine (Spravato) for treatment-resistant depression, and a growing number of psychiatrists offer IV ketamine treatment in private practice.

Major cities — Sydney, Melbourne, Brisbane, Perth — have clinics offering ketamine infusions, and the Australian medical community has been relatively active in researching ketamine's therapeutic applications. Treatment typically requires a referral from a psychiatrist and is available primarily through private clinics.

Costs in Australia range from approximately 500 to 800 AUD per infusion. Private health insurance may provide partial coverage in some cases, particularly for treatment administered in a hospital setting, but out-of-pocket costs remain significant for most patients. Medicare (Australia's public health system) provides limited coverage for ketamine therapy.

New Zealand

New Zealand has more limited access than Australia. Ketamine is available for medical use, and some psychiatrists prescribe it off-label for treatment-resistant depression, but dedicated ketamine clinics are uncommon. Access tends to be through hospital-based psychiatric services or individual private psychiatrists in larger cities like Auckland and Wellington.

The New Zealand regulatory environment is cautious but open to evidence-based use. Patients typically need to demonstrate that conventional treatments have been ineffective before ketamine therapy is considered.

Latin America

Mexico

Mexico has a developing ketamine therapy scene, with private clinics in major cities such as Mexico City, Guadalajara, and Monterrey offering IV infusions. The regulatory environment is less restrictive than in many countries, and treatment costs are generally lower than in the United States — often 200 to 400 USD per infusion.

Some medical tourism companies facilitate ketamine therapy in Mexico for US and Canadian patients seeking lower-cost treatment. If you are considering this option, thorough due diligence is essential — verify the provider's medical credentials, the clinic's safety protocols, and the quality of the medication being used.

Brazil

Brazil has a growing interest in ketamine therapy, supported by active research programs at several major universities. Private clinics in Sao Paulo and Rio de Janeiro offer ketamine infusions, though the market is smaller than in Mexico. The regulatory framework requires that ketamine be administered by qualified medical professionals, and the treatment is primarily available in private practice.

Other Latin American Countries

Elsewhere in Latin America, access is generally limited. Argentina has some clinics offering treatment, particularly in Buenos Aires. In most other countries, ketamine therapy for mental health is either unavailable, very limited, or available only in research settings.

Asia

India

India presents an interesting case. Ketamine is widely available as an anesthetic and is relatively inexpensive. A small but growing number of psychiatrists in major cities — Delhi, Mumbai, Bangalore — offer ketamine therapy for depression, often at costs significantly lower than in Western countries. However, the clinical infrastructure and oversight mechanisms are less developed, and the quality of care can vary widely.

Japan and South Korea

Both countries have strong healthcare systems and active psychiatric research communities, but ketamine therapy for depression remains largely in the research phase. Esketamine has been approved in Japan, and some hospital-based programs offer it for treatment-resistant depression, but private clinics are uncommon.

Southeast Asia and China

Access to ketamine therapy for mental health in these regions is very limited. In some countries, ketamine's association with recreational use has led to strict regulatory controls that make medical use more difficult to access. Patients in these regions who are interested in ketamine therapy typically need to seek treatment abroad.

Finding Providers Internationally

If you are looking for ketamine therapy outside the United States, here are practical strategies for finding a qualified provider:

• Start with medical associations. Many countries have psychiatric or medical associations that can provide referrals to practitioners offering ketamine therapy. National or regional psychiatric societies are often the best starting point.
• Search for published research. Clinicians who have published research on ketamine therapy in a given country are often among the providers offering treatment. A search of medical literature can reveal active researchers and their affiliated institutions.
• Ask for referrals from US providers. Some US-based ketamine clinicians have international networks or can recommend colleagues in other countries. If you have an existing relationship with a US provider, ask whether they know of reputable practitioners where you are headed.
• Verify credentials independently. In any country, confirm that your provider is a licensed physician or psychiatrist. Check with the relevant national or provincial medical licensing body. Be cautious of clinics that are vague about their providers' qualifications.
• Contact teaching hospitals. University-affiliated hospitals in major cities are often at the forefront of offering newer treatments like ketamine therapy, sometimes through clinical programs or research studies.

Telehealth Options for Expats

If you are an American or Canadian expat living abroad, telehealth may or may not be an option depending on where you live. Most US-based telehealth ketamine providers can only prescribe to patients physically located in states where they are licensed. This generally means you need to be in the United States to receive a prescription.

However, some expats coordinate their treatment around visits home — obtaining prescriptions and medication during trips to the US and managing their treatment with remote consultations in between. This approach requires careful planning and cooperation with your prescribing provider.

If you live in a country with its own ketamine therapy infrastructure, establishing care locally is usually the more practical long-term approach. Bring your medical records, treatment history, and any documentation of previous ketamine therapy to help a new provider understand your background.

Cost Comparisons by Region

Treatment costs vary dramatically around the world:

These are approximate ranges and can vary significantly based on the specific clinic, city, and treatment protocol. Always confirm current pricing directly with providers.

What to Consider When Seeking Treatment Abroad

If you are thinking about traveling to another country for ketamine therapy, keep these factors in mind:

• Quality of care matters more than cost. A less expensive treatment is not a bargain if the provider lacks proper training, the clinic lacks appropriate monitoring equipment, or the medication source is questionable. Prioritize safety and quality.
• Continuity of care is essential. Ketamine therapy is most effective as part of an ongoing treatment plan, not a one-time event. Consider how you will maintain treatment continuity — including maintenance sessions and integration support — after returning home.
• Legal and regulatory differences are real. What is routine in one country may be legally complicated in another. Understand the legal status of ketamine in both your home country and your destination before making plans.
• Language barriers can affect care quality. If you do not speak the local language fluently, confirm that the provider and clinical team can communicate with you effectively in a language you are comfortable with.
• Bring your records. Carry a comprehensive medical history, including your psychiatric history, current medications, previous ketamine treatment details (if applicable), and any relevant lab work.
• Plan for follow-up. Before traveling, identify a provider at home who can continue your care. Having a local provider who understands your treatment history is critical for long-term success.

The Global Trajectory

Ketamine therapy is expanding worldwide, driven by a growing body of research and increasing awareness among both clinicians and patients. The pace of this expansion varies by region, influenced by regulatory environments, medical culture, and economic factors. Countries with strong private healthcare sectors and more flexible regulatory frameworks tend to adopt newer treatments faster.

If you are outside the United States and interested in ketamine therapy, the options may be more limited — but they are growing. Stay informed about developments in your country or region, connect with local psychiatric professionals, and advocate for your own care. The global trajectory is clearly moving toward broader access, even if the timeline varies from place to place.

References

• WHO: Depressive Disorder Fact Sheet — World Health Organization overview of depression as a global health concern
• NIMH: Depression Overview — National Institute of Mental Health information on depression treatment, useful as a reference across borders
• NIMH: Cracking the Ketamine Code — NIMH feature on the global research behind ketamine as a depression treatment